GlobeNewsWire
09 Jun 2026, 11:45 UTC · 2h ago
Search tags
Story key points
3 claims · impact-rated
Elraglusib achieved a complete bone marrow response in a heavily pretreated neuroblastoma patient during a Phase 1/2 study. — Clinical proof-of-concept (complete response) in a high-risk population is a high-signal catalyst for biotech valuation.
+0.60Actuate Therapeutics' elraglusib has been selected for evaluation in the international BEACON2 Phase 1/2 platform trial for high-risk pediatric neuroblastoma. — Selection for a prestigious, multi-arm platform trial validates the asset and provides a capital-efficient path to clinical data.
+0.40Elraglusib has received FDA Rare Pediatric Disease designation for neuroblastoma. — Regulatory designations often provide incentives, such as priority review vouchers, which increase the asset's strategic value.
+0.30Ticker attribution
Continue reading
6 related stories
Model heads
The company's drug elraglusib was selected for a landmark clinical trial and has received FDA Rare Pediatric Disease designation.
No ticker relationship head found.
Early access
News Impact Screener scores every headline against the stocks it moves — before the chart reacts. Join the early-access list and get alerted the moment a story hits your tickers.
Impact vectors
3 dimensions · 9 clusters
Market reaction
10 bid · 0 offered
No stock impact ranking available yet.
PRNewsWire
11h ago
